285 related articles for article (PubMed ID: 36230622)
1. The KEAP1-NRF2 System and Esophageal Cancer.
Hirose W; Oshikiri H; Taguchi K; Yamamoto M
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230622
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy.
Zhang J; Jiao Q; Kong L; Yu J; Fang A; Li M; Yu J
Thorac Cancer; 2018 Jun; 9(6):726-735. PubMed ID: 29675925
[TBL] [Abstract][Full Text] [Related]
3. Selective Elimination of NRF2-Activated Cells by Competition With Neighboring Cells in the Esophageal Epithelium.
Hirose W; Horiuchi M; Li D; Motoike IN; Zhang L; Nishi H; Taniyama Y; Kamei T; Suzuki M; Kinoshita K; Katsuoka F; Taguchi K; Yamamoto M
Cell Mol Gastroenterol Hepatol; 2023; 15(1):153-178. PubMed ID: 36115578
[TBL] [Abstract][Full Text] [Related]
4. Methylseleninic acid activates Keap1/Nrf2 pathway via up-regulating miR-200a in human oesophageal squamous cell carcinoma cells.
Liu M; Hu C; Xu Q; Chen L; Ma K; Xu N; Zhu H
Biosci Rep; 2015 Sep; 35(5):. PubMed ID: 26341629
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivity of the transcription factor Nrf2 causes metabolic reprogramming in mouse esophagus.
Fu J; Xiong Z; Huang C; Li J; Yang W; Han Y; Paiboonrungruan C; Major MB; Chen KN; Kang X; Chen X
J Biol Chem; 2019 Jan; 294(1):327-340. PubMed ID: 30409900
[TBL] [Abstract][Full Text] [Related]
6. The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment.
Taguchi K; Yamamoto M
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375248
[TBL] [Abstract][Full Text] [Related]
7.
Akdemir B; Nakajima Y; Inazawa J; Inoue J
Mol Cancer Res; 2017 Nov; 15(11):1570-1578. PubMed ID: 28760781
[TBL] [Abstract][Full Text] [Related]
8. Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function.
Takahashi J; Suzuki T; Sato M; Nitta S; Yaguchi N; Muta T; Tsuchida K; Suda H; Morita M; Hamada S; Masamune A; Takahashi S; Kamei T; Yamamoto M
Cell Rep; 2024 Apr; 43(4):114104. PubMed ID: 38602872
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target.
Ma S; Paiboonrungruan C; Yan T; Williams KP; Major MB; Chen XL
Ann N Y Acad Sci; 2018 Dec; 1434(1):164-172. PubMed ID: 29752726
[TBL] [Abstract][Full Text] [Related]
10. The expression of p-p62 and nuclear Nrf2 in esophageal squamous cell carcinoma and association with radioresistance.
Wang Z; Zhang J; Li M; Kong L; Yu J
Thorac Cancer; 2020 Jan; 11(1):130-139. PubMed ID: 31755241
[TBL] [Abstract][Full Text] [Related]
11. NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation.
He X; Ma Q
Mol Pharmacol; 2009 Dec; 76(6):1265-78. PubMed ID: 19786557
[TBL] [Abstract][Full Text] [Related]
12. NRF2/ACSS2 axis mediates the metabolic effect of alcohol drinking on esophageal squamous cell carcinoma.
Odera JO; Xiong Z; Huang C; Gu N; Yang W; Githang'a J; Odera E; Paiboonrungruang C; Chen X
Biochem J; 2020 Aug; 477(16):3075-3089. PubMed ID: 32776152
[TBL] [Abstract][Full Text] [Related]
13. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
14. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
15. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
16. Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia.
Paiboonrungruang C; Xiong Z; Lamson D; Li Y; Bowman B; Chembo J; Huang C; Li J; Livingston EW; Frank JE; Chen V; Li Y; Weissman B; Yuan H; Williams KP; Ben Major M; Chen X
Redox Biol; 2023 Nov; 67():102901. PubMed ID: 37776708
[TBL] [Abstract][Full Text] [Related]
17. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
Uruno A; Motohashi H
Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
[TBL] [Abstract][Full Text] [Related]
18. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy.
Yoshizaki Y; Mori T; Ishigami-Yuasa M; Kikuchi E; Takahashi D; Zeniya M; Nomura N; Mori Y; Araki Y; Ando F; Mandai S; Kasagi Y; Arai Y; Sasaki E; Yoshida S; Kagechika H; Rai T; Uchida S; Sohara E
Sci Rep; 2017 Jun; 7(1):3945. PubMed ID: 28638054
[TBL] [Abstract][Full Text] [Related]
19. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance.
Jeddi F; Soozangar N; Sadeghi MR; Somi MH; Samadi N
DNA Repair (Amst); 2017 Jun; 54():13-21. PubMed ID: 28415030
[TBL] [Abstract][Full Text] [Related]
20. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2.
He X; Ma Q
J Pharmacol Exp Ther; 2010 Jan; 332(1):66-75. PubMed ID: 19808700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
